Selected ongoing or planned studies with CD38-targeting antibody-containing regimens in other conditions
| Study . | Phase . | Patients . | Treatment . |
|---|---|---|---|
| NCT02841033 | 1/2 | Relapsed or refractory AL amyloidosis | Daratumumab as single agent |
| NCT02816476 (AMYDARA) | 2 | Patients with AL amyloidosis not in VGPR or better after previous treatment | Daratumumab as single agent |
| NCT03067571 | 2 | AML or high-risk myelodysplastic syndrome (relapsed or refractory) | Daratumumab as single agent |
| NCT03011034 | 2 | Transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndrome who are relapsed or refractory to erythropoiesis-stimulating agents | Daratumumab as single agent |
| NCT03095118 | 2 | PGNMID and C3GN | Daratumumab as single agent |
| NCT03098550 | 1/2 | Advanced or metastatic solid tumors | Daratumumab plus nivolumab |
| NCT02488759 (CheckMate358) | 1/2 | Virus-associated tumors such as squamous cell carcinoma of the head and neck, cervix, and anal canal | Nivolumab or nivolumab combinations, including nivolumab plus daratumumab |
| NCT02060188 (CheckMate142) | 2 | Recurrent and metastatic colon cancer | Nivolumab or nivolumab combinations, including nivolumab plus daratumumab |
| NCT03023423 | 1/2 | Previously treated advanced or metastatic non–small cell lung cancer | Daratumumab plus atezolizumab vs atezolizumab |
| NCT02413489 (Carina) | 2 | Relapsed/refractory CD38+ mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma | Daratumumab as single agent |
| NCT02927925 | 2 | Relapsed/refractory NKTCL, nasal type | Daratumumab as single agent |
| NCT01084252 | 1/2 | Relapsed/refractory CD38+ hematological malignancies such as B-cell non-Hodgkin lymphoma, MM, AML, B-ALL, and CLL | Isatuximab as single agent |
| NCT02999633 | 2 | Relapsed or refractory T-ALL and T-LBL | Isatuximab as single agent |
| Study . | Phase . | Patients . | Treatment . |
|---|---|---|---|
| NCT02841033 | 1/2 | Relapsed or refractory AL amyloidosis | Daratumumab as single agent |
| NCT02816476 (AMYDARA) | 2 | Patients with AL amyloidosis not in VGPR or better after previous treatment | Daratumumab as single agent |
| NCT03067571 | 2 | AML or high-risk myelodysplastic syndrome (relapsed or refractory) | Daratumumab as single agent |
| NCT03011034 | 2 | Transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndrome who are relapsed or refractory to erythropoiesis-stimulating agents | Daratumumab as single agent |
| NCT03095118 | 2 | PGNMID and C3GN | Daratumumab as single agent |
| NCT03098550 | 1/2 | Advanced or metastatic solid tumors | Daratumumab plus nivolumab |
| NCT02488759 (CheckMate358) | 1/2 | Virus-associated tumors such as squamous cell carcinoma of the head and neck, cervix, and anal canal | Nivolumab or nivolumab combinations, including nivolumab plus daratumumab |
| NCT02060188 (CheckMate142) | 2 | Recurrent and metastatic colon cancer | Nivolumab or nivolumab combinations, including nivolumab plus daratumumab |
| NCT03023423 | 1/2 | Previously treated advanced or metastatic non–small cell lung cancer | Daratumumab plus atezolizumab vs atezolizumab |
| NCT02413489 (Carina) | 2 | Relapsed/refractory CD38+ mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma | Daratumumab as single agent |
| NCT02927925 | 2 | Relapsed/refractory NKTCL, nasal type | Daratumumab as single agent |
| NCT01084252 | 1/2 | Relapsed/refractory CD38+ hematological malignancies such as B-cell non-Hodgkin lymphoma, MM, AML, B-ALL, and CLL | Isatuximab as single agent |
| NCT02999633 | 2 | Relapsed or refractory T-ALL and T-LBL | Isatuximab as single agent |
AL, amyloid light chain; AML, acute myeloid leukemia; B-ALL, B-cell acute lymphoblastic leukemia; C3GN, C3 glomerulopathy associated with monoclonal gammopathy; CLL, chronic lymphocytic leukemia; NKTCL, NK-/T-cell lymphoma; PGNMID, proliferative glomerulonephritis with monoclonal immune deposit; T-ALL, T-cell acute lymphoblastic leukemia; T-LBL, T-lymphoblastic lymphoma. Other abbreviations are explained in Table 1.